Injectable neurotoxins and fillers: there is no free lunch.
Injection of neurotoxins and filling agents for the treatment of facial aesthetics has increased dramatically during the past few decades due to an increased interest in noninvasive aesthetic improvements. An aging but still youth-oriented population expects effective treatments with minimal recovery time and limited risk of complications. Injectable neurotoxins and soft tissue stimulators and fillers have filled this niche of "lunch-time" procedures. As demand for these procedures has increased, supply has followed with more noncore cosmetic specialty physicians, as well as unsupervised ancillary staff, becoming providers and advertising them as easy fixes. Despite an excellent record of safety and efficacy demonstrated in scores of published studies, injectable agents do carry risks of complications. These procedures require a physician with in-depth knowledge of facial anatomy and injection techniques to ensure patient safety and satisfaction. In general, adverse events are preventable and technique-dependent. Although most adverse events are minor and temporary, more serious complications can occur. The recognition, management, and treatment of poor outcomes are as important as obtaining the best aesthetic results. This review addresses important considerations regarding the complications of injectable neurotoxins and fillers used for "lunch-time" injectable procedures.
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA. jason.emermd@gmail.com
Jason
J
Emer
Heidi
H
Waldorf
D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects*; D001906:Botulism / Q000139:chemically induced / Q000517:prevention & control; D003357:Cosmetic Techniques / Q000009:adverse effects*; D055317:Evidence-Based Practice; D005148:Facial Dermatoses / Q000139:chemically induced / Q000517:prevention & control; D006261:Headache / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007271:Injections, Intradermal; D009498:Neurotoxins / Q000008:administration & dosage / Q000009:adverse effects*; D012060:Rejuvenation
D001672:Biocompatible Materials; D009498:Neurotoxins